Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • Vascular Malformations (Apr 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
The FoxOs are in the ApoM house
MacRae F. Linton, … , Zoe M. Leuthner, Jonathan D. Brown
MacRae F. Linton, … , Zoe M. Leuthner, Jonathan D. Brown
Published April 1, 2022
Citation Information: J Clin Invest. 2022;132(7):e158471. https://doi.org/10.1172/JCI158471.
View: Text | PDF
Commentary

The FoxOs are in the ApoM house

  • Text
  • PDF
Abstract

The prevalence of metabolic syndrome continues to increase globally and heightens the risk for cardiovascular disease (CVD). Insulin resistance is a core pathophysiologic mechanism that causes abnormal carbohydrate metabolism and atherogenic changes in circulating lipoprotein quantity and function. In particular, dysfunctional HDL is postulated to contribute to CVD risk in part via loss of HDL-associated sphingosine-1-phosphate (S1P). In this issue of the JCI, Izquierdo et al. demonstrate that HDL from humans with insulin resistance contained lower levels of S1P. Apolipoprotein M (ApoM), a protein constituent of HDL that binds S1P and controls bioavailability was decreased in insulin-resistant db/db mice. Gain- and loss-of-function mouse models implicated the forkhead box O transcription factors (FoxO1,3,4) in the regulation of both ApoM and HDL-associated S1P. These data have important implications for potential FoxO-based therapies designed to treat lipid and carbohydrate abnormalities associated with human metabolic disease and CVD.

Authors

MacRae F. Linton, Patricia G. Yancey, Zoe M. Leuthner, Jonathan D. Brown

×

Figure 1

FoxO1,3,4 regulate plasma levels of the HDL-ApoM-S1P complex.

Options: View larger image (or click on image) Download as PowerPoint
FoxO1,3,4 regulate plasma levels of the HDL-ApoM-S1P complex.
Hepatic Fo...
Hepatic FoxO transcription factors control the expression of Apom by binding to the promoter and enhancer regions of the gene. ApoM is secreted and forms a complex with plasma S1P. The majority of plasma ApoM-S1P associates with HDL and is found to be associated with pre-β and α (HDL2 and HDL3) migrating subpopulations. ApoM may stimulate the formation of pre–β-HDL during the endothelial lipase– (EL-) and hepatic lipase–mediated (HL-mediated) conversion of α-HDL2 to HDL3 and pre–β-HDL. The HDL-ApoM-S1P complex enhances endothelial barrier integrity and vasodilation. The roles for the HDL-ApoM-S1P complex in insulin resistance, HDL CEC, and RCT have not been clearly demonstrated. FC, free cholesterol; LCAT, lecithin-cholesterol acyltransferase; PL, phospholipid.

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts